Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heide L Ford

Showing results (21-30 of 85) with videos related to

Pageof 9
Sort By:
The International Journal of Biochemistry & Cell Biology|September 16, 2020
Corrigendum to "The Eya phosphatase: Its unique role in cancer" [Int. J. Biochem. Cell Biol. 96 (2018) 165-170]Hengbo Zhou, Lingdi Zhang, Rebecca L Vartuli, et al.
Cancer Research|March 3, 2011
Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agentsChristina Menke, Lianghua Bin, Jacqueline Thorburn, et al.
The Journal of Biological Chemistry|June 6, 2009
Biochemical and functional characterization of six SIX1 Branchio-oto-renal syndrome mutationsAaron N Patrick, Barbara J Schiemann, Kui Yang, et al.
Breast Cancer Research : BCR|November 1, 2014
Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3Chu-An Wang, J Chuck Harrell, Ritsuko Iwanaga, et al.
Molecular Cancer Research : MCR|June 23, 2012
EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistanceTyler P Robin, Anna Smith, Erin McKinsey, et al.
Expert Opinion on Therapeutic Targets|January 4, 2015
The SIX1-EYA transcriptional complex as a therapeutic target in cancerMelanie A Blevins, Christina G Towers, Aaron N Patrick, et al.
Cancer Research|November 9, 2010
Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growthDouglas S Micalizzi, Chu-An Wang, Susan M Farabaugh, et al.
Plos One|January 26, 2011
TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitroChristina Menke, Tatiana Goncharov, Lubna Qamar, et al.
Cancer Research|April 5, 2005
Gene amplification is a mechanism of Six1 overexpression in breast cancerKelly J Reichenberger, Ricardo D Coletta, Aline P Schulte, et al.
Development (Cambridge, England)|April 30, 2017
Negative regulation of endothelin signaling by SIX1 is required for proper maxillary developmentAndre L P Tavares, Timothy C Cox, Robert M Maxson, et al.
Pageof 9

Showing results (21-30 of 85) with videos related to

Sort By:
Pageof 9
The International Journal of Biochemistry & Cell Biology|September 16, 2020
Corrigendum to "The Eya phosphatase: Its unique role in cancer" [Int. J. Biochem. Cell Biol. 96 (2018) 165-170]Hengbo Zhou, Lingdi Zhang, Rebecca L Vartuli, et al.
Cancer Research|March 3, 2011
Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agentsChristina Menke, Lianghua Bin, Jacqueline Thorburn, et al.
The Journal of Biological Chemistry|June 6, 2009
Biochemical and functional characterization of six SIX1 Branchio-oto-renal syndrome mutationsAaron N Patrick, Barbara J Schiemann, Kui Yang, et al.
Breast Cancer Research : BCR|November 1, 2014
Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3Chu-An Wang, J Chuck Harrell, Ritsuko Iwanaga, et al.
Molecular Cancer Research : MCR|June 23, 2012
EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistanceTyler P Robin, Anna Smith, Erin McKinsey, et al.
Expert Opinion on Therapeutic Targets|January 4, 2015
The SIX1-EYA transcriptional complex as a therapeutic target in cancerMelanie A Blevins, Christina G Towers, Aaron N Patrick, et al.
Cancer Research|November 9, 2010
Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growthDouglas S Micalizzi, Chu-An Wang, Susan M Farabaugh, et al.
Plos One|January 26, 2011
TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitroChristina Menke, Tatiana Goncharov, Lubna Qamar, et al.
Cancer Research|April 5, 2005
Gene amplification is a mechanism of Six1 overexpression in breast cancerKelly J Reichenberger, Ricardo D Coletta, Aline P Schulte, et al.
Development (Cambridge, England)|April 30, 2017
Negative regulation of endothelin signaling by SIX1 is required for proper maxillary developmentAndre L P Tavares, Timothy C Cox, Robert M Maxson, et al.
Pageof 9